Oncolytic parvoviruses as cancer therapeutics

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 185-195

  Rommelaere, Jean ^a   Geletneky, Karsten ^a,b   Angelova, Assia L ^a,c   Daeffler, Laurent ^a   Dinsart, Christiane ^a   Kiprianova, Irina ^a   Schlehofer, Joerg R ^a   Raykov, Zahari ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Cancer immunotherapy; Cancer virotherapy; Clinical trial; Immunomodulation; Oncolysis; Oncosuppression; Parvoviruses

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; GRANZYME B; NONSTRUCTURAL PROTEIN 1; ONCOLYTIC PARVOVIRUS; PERFORIN; RITUXIMAB; SMAD4 PROTEIN; IMMUNOLOGIC FACTOR; ONCOLYTIC VIRUS;

ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BURKITT LYMPHOMA; CANCER IMMUNIZATION; CANCER INHIBITION; CELL KILLING; CLINICAL TRIAL; CROSS PRESENTATION; DRUG CYTOTOXICITY; DRUG SELECTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOMODULATION; INTERFERON PRODUCTION; LUNG METASTASIS; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN METASTASIS; SURVIVAL RATE; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; VIREMIA; VIRUS CELL INTERACTION; VIRUS REPLICATION; ANIMAL; CLINICAL TRIAL (TOPIC); GENETICS; METABOLISM; NEOPLASMS; PARVOVIRIDAE; PATHOLOGY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PARVOVIRUS;

ANIMALIA; H-1 PARVOVIRUS; PARVOVIRUS; RODENTIA;

EID: 77953537989     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.011     Document Type: Review

References (48)

1. Tattersall P. The evolution of parvoviral taxonomy. The parvoviruses 2006, 5-14. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
2. Cornelis J.J., Deleu L., Koch U., Rommelaere J. Parvovirus oncosuppression. The parvoviruses 2006, 365-384. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
3. Di Piazza M., Mader C., Geletneky K., Herrero y Calle M., Weber E., Schlehofer J., et al. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol 2007, 81:4186-4198.
4. Cotmore S.F., Tattersall P. Parvoviral host range and cell entry mechanisms. Adv Virus Res 2007, 70:189-232.
5. Rommelaere J., Giese N., Cziepluch C., Cornelis JJ Parvoviruses as anti-cancer agents. Viral therapy of human cancers 2005, 627-675. Marcel Dekker, New York. J.G. Sinkovics, J.C. Horvath (Eds.).
6. Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008, 89:1-47.
7. Nüesch J.P.F. Regulation of non-structural protein functions by differential synthesis, modification and trafficking. The parvoviruses 2006, 275-289. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
8. Nüesch J.P.F., Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc Natl Acad Sci USA 2007, 104:12482-12487.
9. Moehler M.H., Zeidler M., Wilsberg V., Cornelis J.J., Woelfel T., Rommelaere J., et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation and cross-presentation by dendritic cells. Hum Gene Ther 2005, 16:996-1005.
10. Faisst S., Schlehofer J.R., zur Hausen H. Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation. J Virol 1989, 63:2152-2158.
11. Dupressoir T., Vanacker J.M., Cornelis J.J., Duponchel N., Rommelaere J. Inhibition by parvovirus H-1 of the formation of tumors in nude mice and colonies in vitro by transformed human mammary epithelial cells. Cancer Res 1989, 49:3203-3208.
12. Faisst S., Guittard D., Benner A., Cesbron J.Y., Schlehofer J.R., Rommelaere J., et al. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int J Cancer 1998, 75:584-589.
13. Van Pachterbeke C., Tuynder M., Cosyn J.P., Lespagnard L., Larsimont D., Rommelaere J. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 1993, 55:672-677.
14. Van Pachterbeke C., Tuynder M., Brandenburger A., Leclercq G., Borras M., Rommelaere J. Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur J Cancer 1997, 33:1648-1653.
15. Geletneky K., Herrero y Calle M., Rommelaere J., Schlehofer J.R. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health 2005, 52:327-330.
16. Herrero y Calle M., Cornelis J.J., Herold-Mende C., Rommelaere J., Schlehofer J.R., Geletneky K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 2004, 109:76-84.
17. Angelova A.L., Aprahamian M., Balboni G., Delecluse H.-J., Feederle R., Kiprianova I., et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies. Mol Ther 2009, 17:1164-1172.
18. Geletneky K., Herrero y Calle M., Herold-Mende C., Sommer C., Koch R., Rommelaere J., et al. Complete remission of advanced autologous intracranial gliomas by oncolytic Parvovirus H1. Eur J Cancer 2005, 3(Suppl.):53.
19. Hutt M.S., Burkitt D.P. Aetiology of Burkitt's lymphoma. Lancet 1973, 1:439.
20. Chuang S.S., Huang W.T., Hsieh P.P., Jung Y.C., Ye H., Du M.Q., et al. Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathol 2008, 52:427-435.
21. Abali H., Urün Y., Oksüzoĝlu B., Budakoĝlu B., Yildirim N., Güler T., et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008, 26:401-406.
22. Heslop H.E. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematol 2005, 1:260-266.
23. Wilop S., Galm O., Dada R., Osieka R., Jost E. Rituximab-associated changes in platelet count in patients with non-Hodgkin lymphoma. Leuk Lymph 2008, 49:2116-2124.
24. Ghetie M.A., Bright H., Vitetta E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001, 97:1392-1398.
25. Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T. p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J 1991, 10:2879-2887.
26. Flamand L., Stefanescu I., Ablashi D.V., Menezes J. Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol 1993, 67:6768-6777.
27. Arcenas R., Widen R.H. Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus. BMC Microbiol 2002, 2:20.
28. Hudson W.A., Li Q., Le C., Kersey J.H. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia 1998, 12:2029-2033.
29. Guetta E., Graziani Y., Tal J. Suppression of Ehrlich ascites tumors in mice by minute virus of mice. J Natl Cancer Inst 1986, 76:1177-1180.
30. McKisic M.D., Paturzo F.X., Smith A.L. Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. Transplantation 1996, 61:292-299.
31. McKisic M.D., Macy J.D., Delano M.L., Jacoby R.O., Paturzo F.X., Smith A.L. Mouse parvovirus infection potentiates allogeneic skin graft rejection and induces syngeneic graft rejection. Transplantation 1998, 65:1436-1446.
32. Giese N.A., Raykov Z., DeMartino L., Vecchi A., Sozzani S., Dinsart C., et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002, 9:432-442.
33. Raykov Z., Balboni G., Aprahamian M., Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004, 109:742-749.
34. Raykov Z., Grekova S., Galabov A.S., Balboni G., Koch U., Aprahamian M., et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep 2007, 17:1493-1499.
35. Toolan H.W., Saunders E.L., Southam C.M., Moore A.E., Levin A.G. H-1 virus viremia in the human. Proc Soc Exp Biol Med 1965, 119:711-715.
36. Lang S.I., Giese N.A., Rommelaere J., Dinsart C., Cornelis J.J. Humoral immune responses against minute virus of mice vectors. J Gene Med 2006, 8:1141-1150.
37. Moehler M., Zeidler M., Schede J., Rommelaere J., Galle P.R., Cornelis J.J., et al. Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Ther 2003, 10:477-480.
38. Uhl M., Kepp O., Jusforgues-Saklani H., Vicencio J.M., Kroemer G., Albert M.L. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ 2009, 16:991-1005.
39. Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009, 9:353-363.
40. Angelova A.L., Aprahamian M., Grekova S.P., Hajri A., Leuchs B., Giese N.A., et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 2009, 15:511-519.
41. Raykov Z., Savelyeva L., Balboni G., Giese T., Rommelaere J., Giese N.A. B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J Virol 2005, 79:3517-3524.
42. Raykov Z., Grekova S., Leuchs B., Aprahamian M., Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer 2008, 122:2880-2884.
43. Schmitz-Winnenthal F.H., Escobedo L.V., Beckhove P., Schirrmacher V., Bucur M., Ziouta Y., et al. Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma. Int J Oncol 2006, 28:1419-1428.
44. Battaglia A., Buzzonetti A., Baranello C., Ferrandina G., Martinelli E., Fanfani F., et al. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother 2009, 58:1363-1373.
45. Wolter T.R., Wong R., Sarkar S.A., Zipris D. DNA microarray analysis for the identification of innate immune pathways implicated in virus-induced autoimmune diabetes. Clin Immunol 2009, 132:103-115.
46. Prestwich R.J., Ilett E.J., Errington F., Diaz R.M., Steele L.P., Kottke T., et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 2009, 15:4374-4381.
47. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484.
48. Le Cesne A., Dupressoir T., Jamin N., Spielmann M., Le Chevalier T., Sancho-Garnier H., et al. Intra-lesional administration of a live virus, parvovirus H-1, in cancer patients: a feasibility study. Proc Am Soc Clin Oncol 1993, 12:297.